Acumen Pharmaceuticals (ABOS)
(Real Time Quote from BATS)
$2.41 USD
-0.09 (-3.60%)
Updated Sep 23, 2024 12:42 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Acumen Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 244 | 178 | 194 | 44 | 7 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 4 | 1 | 1 |
Total Current Assets | 247 | 180 | 199 | 44 | 7 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 63 | 16 | 32 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 310 | 197 | 230 | 44 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 6 | 4 | 0 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 8 | 5 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 62 | 18 |
Total Liabilities | 43 | 8 | 5 | 63 | 19 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 489 | 360 | 353 | 8 | 8 |
Retained Earnings | -223 | -170 | -128 | -27 | -20 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 267 | 189 | 225 | -19 | -11 |
Total Liabilities & Shareholder's Equity | 310 | 197 | 230 | 44 | 7 |
Total Common Equity | 267 | 189 | 225 | -19 | -11 |
Shares Outstanding | 57.90 | 40.50 | 40.40 | NA | NA |
Book Value Per Share | 4.61 | 4.66 | 5.57 | 0.00 | 0.00 |
Fiscal Year End for Acumen Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 260 | 253 | 244 | 215 | 145 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 3 | 3 | 3 | 5 |
Total Current Assets | 267 | 256 | 247 | 219 | 150 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 21 | 44 | 63 | 67 | 27 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 0 | 0 | 0 |
Total Assets | 289 | 301 | 310 | 286 | 177 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 1 | 0 | 0 |
Accrued Expenses | 11 | 5 | 11 | 5 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 8 | 13 | 6 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 29 | 30 | 30 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 45 | 39 | 43 | 6 | 9 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 502 | 500 | 489 | 487 | 363 |
Retained Earnings | -258 | -238 | -223 | -206 | -193 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 244 | 262 | 267 | 280 | 169 |
Total Liabilities & Shareholder's Equity | 289 | 301 | 310 | 286 | 177 |
Total Common Equity | 244 | 262 | 267 | 280 | 169 |
Shares Outstanding | 60.00 | 60.00 | 57.90 | 57.80 | 41.00 |
Book Value Per Share | 4.07 | 4.37 | 4.61 | 4.85 | 4.12 |